Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Ulcerative colitis
Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
Overview
Diagnose ulcerative colitis, describe its continuous colonic extent and activity, and deliver steroid-sparing medical care with timely surveillance and surgical discussion.
UC is diagnosed from a compatible pattern of chronic colitis after exclusion of infection and mimics such as drug injury, ischaemia and Crohn disease. Ileocolonoscopy defines extent and permits biopsies from affected and apparently normal segments. In a severe flare, full colonoscopy and bowel preparation may increase risk; limited flexible sigmoidoscopy with careful sampling is usually more appropriate. Histology supports chronicity but early disease can be non-specific. A stool culture and Clostridioides difficile test are important during an apparent flare because infection and inflammation may coexist.
Treatment aims for clinical remission without corticosteroid and objective control of inflammation. Extent guides the route of 5-ASA: suppositories reach proctitis, enemas reach further and oral therapy treats more proximal colon. Adherence often matters more than unnecessary switching, so ask about formulation, routine and barriers without blame. Patients with persistent activity, adverse prognostic features or steroid dependence need timely advanced therapy or surgical review. Longstanding colonic inflammation increases dysplasia risk; surveillance is risk-stratified by duration, extent, inflammatory burden, family history, post-inflammatory polyps and primary sclerosing cholangitis.
Key points
Ulcerative colitis is chronic mucosal inflammation beginning in the rectum and extending proximally in a usually continuous pattern; extent can change over time or appear modified by treatment.
Bloody diarrhoea, urgency, tenesmus and nocturnal stool are typical, but diagnosis still requires stool infection assessment, endoscopy and histology rather than symptoms alone.
Record proctitis, left-sided or extensive disease and quantify activity because topical reach, systemic risk, surveillance and treatment selection all depend on them.
For mild to moderate disease, mesalazine delivered to the involved mucosa is foundational; combined oral and rectal delivery is often more effective than ignoring distal treatment.
Corticosteroids induce remission when 5-ASA is insufficient but should not maintain it; relapse during taper or repeated courses requires escalation to steroid-sparing therapy.
Moderate to severe disease may require biologic or small-molecule therapy selected through current NICE and BSG guidance, individual safety assessment and shared decision-making.
Increasing bloody stool frequency, tachycardia, fever, anaemia or raised inflammatory markers can indicate acute severe ulcerative colitis and requires hospital assessment, not an outpatient prescription change.
Aetiology
01
Genetic immune susceptibility
Polygenic variants alter epithelial and immune regulation, increasing risk within families without following a simple Mendelian inheritance pattern.
02
Microbiome and barrier interaction
An inappropriate immune response to intestinal microbiota develops across a susceptible colonic barrier and sustains chronic mucosal inflammation.
03
Environmental modifiers
Age, prior enteric exposure, smoking history, medicines and other environmental factors influence risk or activity, but no single trigger explains most cases.
Pathophysiology
1
Rectal mucosal inflammation
Inflammation begins in the rectum and usually extends proximally in a continuous pattern limited primarily to mucosa and superficial submucosa.
2
Ulceration and impaired absorption
Crypt inflammation, epithelial loss and friability cause blood, mucus, urgency, diarrhoea and reduced colonic water absorption.
3
Chronic remodelling and dysplasia
Repeated inflammatory injury alters architecture and can produce dysplastic clones, with cancer risk related to duration, extent and inflammatory burden.
Clinical features and red flags
Distal colitis
Rectal bleeding, mucus, urgency, tenesmus and frequent small stools may occur without substantial systemic illness and can respond particularly well to topical therapy.
Extensive active disease
Frequent bloody diarrhoea, nocturnal symptoms, cramping, weight loss, anaemia and raised inflammation suggest a larger mucosal burden and higher systemic risk.
Acute severe physiology
High stool frequency with fever, tachycardia, anaemia or marked inflammatory response should prompt hospital admission and formal severe-colitis assessment.
Extra-intestinal disease
Peripheral arthritis, axial spondyloarthritis, uveitis, skin inflammation and hepatobiliary disease may track intestinal activity or follow an independent course.
Treatment toxicity
Renal impairment on mesalazine, steroid effects, cytopenia on immunomodulators and infection on immune therapy can mimic or compound an intestinal deterioration.
Cancer and dysplasia signal
New altered pattern, unexplained iron deficiency, weight loss, stricture or visible lesion in longstanding colitis needs high-quality colonoscopic assessment rather than attribution to routine flare.
Red flags requiring action
Suspected acute severe colitis requires same-day hospital assessment with gastroenterology and colorectal surgery involvement from admission.
Investigations
01Stool culture and Clostridioides difficile testingFirst step
Why
Exclude treatable infection at diagnosis and during clinically important flares.
Interpretation and limitations
A positive result can coexist with UC activity and requires coordinated antimicrobial and IBD decisions; a negative panel does not itself prove inflammatory relapse.
02Faecal calprotectin
Why
Estimate neutrophilic intestinal inflammation and support non-invasive follow-up.
Interpretation and limitations
Interpret trends with symptoms and local assay thresholds; infection, NSAIDs and other bowel inflammation can raise it, while very distal mild disease may produce less marked elevation.
03Ileocolonoscopy with mapped biopsies
Why
Confirm chronic colitis, define extent and exclude Crohn disease or another mimic.
Interpretation and limitations
Continuous inflammation from the rectum supports UC, but treatment can create patchiness; histological chronicity and terminal ileal findings require integrated interpretation.
04Blood count, CRP, renal, liver and albumin profile
Why
Assess severity, anaemia, dehydration, nutrition and treatment safety.
Interpretation and limitations
Anaemia, thrombocytosis, low albumin and inflammatory response indicate burden; renal function also provides a mesalazine
Differential diagnosis
01
Infectious colitis
Acute exposure and positive stool testing support infection; Clostridioides difficile can also trigger a flare and should be sought before immunosuppression escalation.
02
Crohn disease
Skip lesions, small-bowel or perianal involvement and transmural stricturing or fistulation favour Crohn disease over continuous mucosal UC.
03
Ischaemic or microscopic colitis
Abrupt segmental pain and bleeding after low flow suggests ischaemia, while normal mucosa with watery non-bloody stool and diagnostic biopsies suggests microscopic colitis.
Management
01CONFIRMEstablish diagnosis and extentFirst stepPersistent bloody diarrhoea, urgency or tenesmus raises suspicion of new ulcerative colitis.+
1Assess haemodynamic and systemic severity first, admitting suspected acute severe disease rather than progressing through a routine outpatient pathway.
2Obtain blood and stool tests, including infection assessment, medication and travel history, and examine for abdominal, perianal and extra-intestinal findings.
3Perform ileocolonoscopy with systematic biopsies when safe, using limited sigmoidoscopy instead if severe colitis makes full examination hazardous.
4Document activity, proctitis versus left-sided or extensive involvement, nutrition, extra-intestinal disease and individual cancer-surveillance factors.
02MILD-MODERATEDeliver mesalazine to the inflamed colonObjective mild to moderate activity is present without systemic severe-colitis criteria.+
Complications
01
Acute severe colitis and megacolon
Intense inflammation causes systemic toxicity, anaemia and colonic dilatation, with perforation risk and a need for timely rescue therapy or colectomy.
02
Thrombosis and nutritional loss
Active disease increases venous thromboembolism risk, while bleeding, protein loss and reduced intake cause anaemia and malnutrition.
03
Colorectal cancer
Longstanding extensive inflammatory burden increases dysplasia and cancer risk, supporting high-quality risk-based surveillance rather than symptom-led colonoscopy alone.
Monitoring and follow-up
Record bloody stool frequency, urgency, nocturnal symptoms, weight, function and cumulative steroid exposure at each clinically important review.
Use faecal calprotectin and CRP trends with symptoms, recognising that discordance may require endoscopic reassessment rather than automatic treatment escalation.
Monitor renal function for mesalazine and follow drug-specific blood, infection and safety schedules for immunomodulator or advanced therapy.
Assess iron deficiency, nutrition, bone health, mental wellbeing, vaccination, fertility and extra-intestinal manifestations as part of ongoing care.
Confirm mucosal response when it will guide de-escalation, switch or surveillance quality; absence of bleeding alone is not proof of healed disease.
Maintain a risk-based dysplasia-surveillance register with active recall, expert pathology access and clear ownership of every biopsy result.
Special situations
Route is part of the prescription
An oral drug may not optimally treat the rectum. Suppositories and enemas place active treatment at the site producing urgency and bleeding.
Patchiness can be treatment-created
Although untreated UC is usually continuous, topical or systemic treatment can produce relative rectal sparing or uneven healing and should not automatically relabel disease as Crohn.
Infection and flare can coexist
Finding C. difficile does not exclude active UC. Antimicrobial, isolation and anti-inflammatory decisions need joint specialist assessment rather than a binary choice.
Colectomy changes the disease landscape
Removing colon cures colonic inflammation but not every extra-intestinal manifestation, and pouch or stoma function creates distinct long-term care needs.
Inflammation drives cancer risk
Duration and extent matter, but cumulative histological activity also influences dysplasia risk, making durable inflammatory control part of cancer prevention.
Common pitfalls
01
Diagnosing UC from bloody diarrhoea without stool infection testing and histological confirmation.
02
Prescribing oral mesalazine for distressing proctitis without offering an effective rectal preparation or discussing how to use it.
03
Continuing systemic corticosteroids as maintenance because bleeding returns during taper.
04
Managing suspected acute severe colitis through routine outpatient messages and delayed blood tests.
05
Treating a raised calprotectin as UC-specific without considering infection, NSAID use or another inflammatory disorder.
06
Delaying surgical discussion until emergency colectomy removes time for stoma education, fertility counselling and shared choice.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA
Treating active proctitis
A patient has mild active ulcerative proctitis with rectal bleeding and urgency but no systemic illness. Which initial treatment principle best targets the involved mucosa?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Colectomy removes colitis and colorectal cancer risk from retained colon, but surgery creates new functional, fertility, stoma or pouch considerations and should be discussed before emergency circumstances.
Abdominal distension, tenderness, systemic toxicity or reduced stool passage can indicate toxic megacolon or perforation and needs urgent imaging and surgical review.
Major haemorrhage, shock, severe electrolyte disturbance or venous thromboembolism is an emergency and should not await elective IBD clinic contact.
A painful red eye with photophobia or reduced vision suggests uveitis and requires urgent ophthalmology assessment rather than routine optometry alone.
Worsening symptoms during immunosuppression require infection testing and medicine-toxicity assessment before assuming uncontrolled UC.
baseline and liver tests may reveal associated hepatobiliary disease.
05Limited flexible sigmoidoscopy
Why
Assess active severe colitis and obtain biopsies with less procedural burden.
Interpretation and limitations
Describe ulceration and extent reached, and request cytomegalovirus assessment when clinically relevant; avoid excessive insufflation or a full prepared colonoscopy in toxic severe disease.
06Surveillance colonoscopy
Why
Detect dysplasia in patients with long-standing colonic disease at increased risk.
Interpretation and limitations
Use high-quality inspection by an experienced service and a risk-based interval; visible lesions, invisible dysplasia and active inflammation require different MDT pathways.
1
Select rectal suppository or enema according to distal extent and add appropriate oral mesalazine when disease is left-sided, extensive or insufficiently controlled.
2Explain administration, formulation and expected response, addressing adherence barriers and monitoring renal function according to product and local guidance.
3If response is inadequate, confirm adherence and infection status, then optimise 5-ASA and consider a time-limited topical or systemic corticosteroid strategy.
4After remission, continue an effective maintenance 5-ASA plan and reassess objectively when symptoms, biomarkers or adherence change.
03ESCALATEAchieve steroid-free controlEscalationDisease is moderate to severe, steroid dependent, frequently relapsing or objectively active despite optimised conventional therapy.+
1Restage activity and extent, exclude infection, review adherence and quantify prior steroid burden before declaring the current mechanism ineffective.
2Screen for infection, update vaccination and discuss reproductive, thrombotic, cardiovascular and malignancy factors before advanced treatment selection.
3Choose a biologic or small molecule using current NICE access, likely efficacy, speed, route, safety, patient preference and extra-intestinal needs.
4DefinitiveSet an early objective response target and bring colorectal surgery into discussion when disease remains refractory, dysplasia develops or quality of life favours a definitive option.
04SURVEILPrevent and detect colitis-associated cancerThe duration and extent of colitis place the patient within an IBD surveillance programme.+
1Define risk from disease extent, duration, inflammatory burden, family history, post-inflammatory polyps, strictures, dysplasia and primary sclerosing cholangitis.
2Schedule high-quality surveillance at the risk-appropriate interval, aiming for good disease control and adequate bowel preparation before inspection.
3Manage visible dysplasia according to resectability and surrounding mucosa, and confirm invisible dysplasia through expert pathology and repeat expert assessment.
4Discuss colectomy or continued intensive surveillance in a specialist MDT when dysplasia risk cannot be managed safely by endoscopic resection alone.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
Induces and maintains remission in mild to moderate UC by treating involved colonic mucosa.
Mesalazine
Oral and rectal regimen matched to extent, formulation and licensed product instructions.
Check renal function before and during treatment; rare nephrotoxicity, pancreatitis, blood dyscrasia or paradoxical worsening requires prompt review, and brands are not always dose-equivalent.
Controls active disease when optimised 5-ASA is insufficient or presentation is more severe.
Corticosteroid
Time-limited topical, oral or intravenous induction course selected by severity.
Never use for maintenance; infection, hyperglycaemia, mood effects, osteoporosis, thrombotic risk and adrenal suppression require mitigation, with a predefined taper and escalation plan.
Provides steroid-sparing control for moderate to severe or conventionally refractory ulcerative colitis.
Advanced immune therapy
Specialist induction and maintenance schedule under current NICE and local commissioning criteria.
Class-specific infection, malignancy, cardiovascular, thrombotic, hepatic and pregnancy considerations differ substantially; complete screening and avoid choosing solely by convenience.